Gastrointestinal Cancer

Zev A. Wainberg, MD, discusses the mechanism of action of zanidatamab and its FDA approval as a new frontline option for HER2-positive gastric cancer.

Neeta Somaiah, MD, discusses efficacy data for bezuclastinib plus sunitinib from the Peak study in advanced gastrointestinal stromal tumors.

The FDA has approved zanidatamab plus chemotherapy with/without tislelizumab in frontline HER2-positive GEA based on data from HERIZON-GEA-01.

The oral pan-RAS molecular glue ERAS-0015 has received FDA fast track designation for the management of metastatic pancreatic adenocarcinoma.

The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.

Meredith Pelster, MD, MSCI, discusses phase 2a data for atebimetinib plus chemotherapy and the design of a phase 2 trial in pancreatic cancer.

Dr Valerin discusses the role of liposomal irinotecan in pancreatic cancer management and factors influencing the decision to use this agent in practice.

Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.

Paul E. Oberstein, MD, discusses a personalized mRNA vaccine being evaluated in pancreatic ductal adenocarcinoma and why it matters.

Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.

Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.

Paul E. Oberstein, MD, discusses data for an autogene cevumeran–based regimen in pancreatic ductal adenocarcinoma.

Erman Akkus, MD, discusses how oncologists can weigh cross-trial comparisons and reach practical second-line decisions in advanced HCC.

The FDA has issued a CRL to the NDA seeking the approval of the investigational agent 177Lu-edotreotide for the treatment of patients with GEP-NETs.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

Erman Akkus, MD, discusses why second-line treatment in advanced hepatocellular carcinoma remains undefined and how reconstructed patient data can help fill it.

Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.